Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;13(3):277-283.
doi: 10.1111/1759-7714.14277. Epub 2021 Dec 12.

Update on adjuvant therapy in completely resected NSCLC patients

Jeong Uk Lim  1 , Chang Dong Yeo  2
Affiliations
Review

Update on adjuvant therapy in completely resected NSCLC patients

Jeong Uk Lim et al. Thorac Cancer. 2022 Feb.

Abstract

In patients with completely resected non-small cell lung cancer (NSCLC), postoperative adjuvant chemotherapy has been associated with improvement in survival by minimizing the risk of recurrence. For years, systemic chemotherapy including platinum based regimen has been a mainstay treatment modality of adjuvant treatment after complete resection. ADAURA study showed that among completely resected IB to IIIA NSCLC, disease-free survival was significantly better in patients under adjuvant osimertinib than a placebo group. After the advent of a variety of new treatment regimens, such as third generation TKI and immunotherapy, the landscape of postoperative adjuvant treatment has been changing. In this review, we discuss some key issues regarding choice of adjuvant treatment after complete resection in NSCLC, and provide further updates on recent advances in treatment modalities.

Keywords: adjuvant; biomarker; immunotherapy; non-small cell lung cancer; osimertinib.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this article. The authors have stated that they have no conflicts of interest.

References

    1. Goldstraw P, Chansky K, Crowley J, Rami‐Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. - PubMed
    1. Vansteenkiste J, Wauters E, Reymen B, Ackermann CJ, Peters S, De Ruysscher D. Current status of immune checkpoint inhibition in early‐stage NSCLC. Ann Oncol. 2019;30(8):1244–53. - PubMed
    1. Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, et al. Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancer. Cochrane Database Syst Rev. 2015;3:CD011430. - PMC - PubMed
    1. Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y, Ellis PM. Postoperative adjuvant systemic therapy in completely resected non‐small‐cell lung cancer: a systematic review. Clin Lung Cancer. 2017;18(3):259–73.e8. - PubMed
    1. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin‐based adjuvant chemotherapy in patients with completely resected non‐small‐cell lung cancer. N Engl J Med. 2004;350(4):351–60. - PubMed

MeSH terms